genedrive plc

("genedrive" or the "Company")

Initial overseas orders of the Genedrive® MT-RNR1 ID Kit

genedrive plc (AIM: GDR), the point of care Pharmacogenetic testing company, announces that initial orders of the Genedrive® MT-RNR1 products have been received from France, Austria, Greece, Saudi Arabia, Turkey and the Netherlands. This follows the Company recently confirming that commercial distribution agreements for the genedrive test for antibiotic induced hearing loss ("AIHL") in a number of countries had been signed.

The initial orders will support genedrive's international distribution partners in promotion and in-country evaluation activities in their respective countries, to provide more extensive access to this life-changing test.

James Cheek, Chief Executive Officer of genedrive plc, said: "We are delighted to see the first orders come in from those countries we have signed distribution agreements with. We look forward to the continued expansion of our international sales throughout 2024 as we drive forward with our sales and marketing strategies and deliver value to our shareholders."

For further details, please contact:

About genedrive plc (http://www.genedriveplc.com) 

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need pharmacogenetic platform for the diagnosis of genetic variations. This helps clinicians to quickly access key genetic information that will help them make the right choices over the right medicine or dosage to use for an effective treatment. Based in the UK, the Company is at the forefront of work on Point of Care pharmacogenetics. Pharmacogenetics looks at how your genetics impacts a medicines ability to work for you. Therefore, by using pharmacogenetics, medicines can be made safer and more effective. The Company has launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. This test allows clinicians to make a decision on antibiotic use within 26 minutes; ensuring vital care is delivered with no negative impact on the patient pathway.

The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.